Pancreatic cancer
Conditions
Interventions
Esketamine Group:Intravenous esketamine at a dose of 0.15 mg/kg/h, starting from before skin incision after anesthesia induction, continuing until wound closure or up to 4 hours (total dose not exceed
Control Group:Intravenous infusion of 0.9% sodium chloride, same volume, with infusion rate matched to the esketamine group
Sponsors
The First Affiliated Hospital of Soochow University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Age 18-80 years; 2.ASA physical status I-III; 3.Scheduled for elective open or laparoscopic pancreatic resection for pancreatic cancer (including pancreaticoduodenectomy (PD), total pancreatectomy, distal pancreatectomy); 4.Sign the informed consent form, agree to participate in this study, and commit to completing postoperative follow-up;
Exclusion criteria
Exclusion criteria: 1.Uncontrolled hypertension (SBP > 180 mmHg or DBP > 110 mmHg); 2.History of angina pectoris or myocardial infarction within the past 3 months; 3.Severe hepatic dysfunction (Child-Pugh class C); 4.Renal insufficiency (eGFR =3 months) of analgesic or psychotropic medications; 10.Patients unable to communicate effectively or comprehend assessment scales;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| OBAS score at 24 hours postoperatively;Incidence of moderate to severe depression at 7 days postoperatively; | — |
Secondary
| Measure | Time frame |
|---|---|
| NRS pain score at 1 month postoperatively;Incidence of moderate to severe depression at 1 month postoperatively;NRS pain score at 3 months postoperatively;Incidence of moderate to severe depression at 3 months postoperatively; | — |
Countries
China
Contacts
Public ContactPeng Ke
The First Affiliated Hospital of Soochow University
Outcome results
None listed